Bacteriophages Therapy Market (By Targeted Bacteria - Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella. By Disease Indication - Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis. By Route of Administration - Oral, Topical, Parenteral. By Geography - North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Global industry analysis, size, share, growth, trends, and forecast, 2021 - 2031.

The Global Bacteriophages Therapy Market was $1.05 Billion in 2020, and it is expected to reach $3.6 Billion by 2031. It is eventually growing at a commendable compound annual growth rate (CAGR) of 11.6% between 2021-2031. The current pandemic of COVID-19 is expected for the market of Bacteriophages Therapy to grow. This growth is supported by the fact that one can get treated for deadly bacterial infection without any other medication. However, it can’t treat COVID, but it can treat a number of other critical infections caused due to many other factors such as rotten food, and expired dairy. The Bacteriophages Therapy Market is primarily driven by its significant role in molecular and genetics biology. The growing importance of bacteriophage in the bacterial fermentation process is also projected to boost the market growth. Recent investments in Bacteriophages Therapy are expected to drive the market positively. Moreover, the significant role of bacteriophage in manufacturing such as biotechnology and food products is projected to propel the market growth over the forecast period.

Global Bacteriophages Therapy in Ready to Eat Food Segment Is Estimated to Witness Remarkable Growth

Source: SAI Research

The global Bacteriophages Therapy Market has been segmented (By Targeted Bacteria - Escherichia coli, Staphylococcus aureus, Streptococcus, Pseudomonas aeruginosa, Salmonella. By Disease Indication - Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound and Skin Infections, Cystic Fibrosis. By Route of Administration - Oral, Topical, Parenteral. By Geography - North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Global industry analysis, size, share, growth, trends, and forecast, 2021 - 2031. Bacteriophages Therapy for Escherichia coli is estimated to witness remarkable growth over the forecast period as it has the majority of cultivated viruses that have the capability to culminate in the widest range of bacteria.

By Region, North America is Holding the Major Market Share

The global Bacteriophages Therapy Market has been geographically segmented into North America, Asia Pacific, Latin America, Middle East, and Africa region. In addition to this, North America Bacteriophages Therapy Market is holding the largest market share currently and is estimated to show a steady compound annual growth rate in the upcoming forecast period due to prominent phage entities in the U.S., faster commercialization process, a large base of patients suffering from bacterial infection, and rising prevalence of antibiotic resistance. Moreover, the use of bacteriophages in the environment and food sector, and evolved research infrastructure with numerous initiatives in introducing new technologies is projected to bolster the market growth in the region. Asia Pacific region is anticipated to show the fastest growth rate in the forecast period due to transforming biotechnology infrastructure, changing agriculture methods, and positive government initiatives. Europe and LAMEA region are also projected to register a decent growth rate over the forecast period from 2020 to 2028.

Major Players in Global Bacteriophages Therapy Market

Some of the key players in the global Bacteriophages Therapy Market include Adaptive Phage Therapeutics, Armata Pharmaceuticals, Inc., BiomX Ltd., ContraFect Corporation, Enbiotix, Inc.,Eligo Bioscience SA, Eliava Biopreparations Ltd., Fixed-phage Ltd., Intodeworld, Inc., InnoPhage, Ltd, Intralytix, Inc., Locus Biosciences, Inc., Micreos BV, Nextbiotics, OPTIPHARM Co., Ltd., PhagePro, Inc., Phagelux, Inc., Pherecydes Pharma, Phagomed Biopharma GmbH., Phi Therapeutics, TechnoPhage and Others.

 Scope of the Report:

The Global Bacteriophages Therapy Market Has Been Segmented into:

Global Bacteriophages Therapy Market: By Targeted Bacteria

• Escherichia coli,
• Staphylococcus aureus,
• Streptococcus,
• Pseudomonas aeruginosa,
• Salmonella,
• Others

Global Bacteriophages Therapy Market: By Disease Indication

• Urinary Tract Infections,
• Chronic Otitis,
• Dental Extraction,
• Chronic Ulcerative Colitis,
• Bone Infection,
• Wound and Skin Infections,
• Cystic Fibrosis,
• Others (Eye Infections, Lung Infections, Oral Infections, GI Infections etc.)

Global Bacteriophages Therapy Market: By Route of Administration

• Oral,
• Topical,
• Parenteral
• Others

Global Bacteriophages Therapy Market: By Region

• North America
• USA
• Canada
• Mexico
• Rest of North America
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• India
• China
• Japan
• South Korea
• Rest of Asia Pacific
• Latin America, Middle East & Africa
• Brazil
• South Africa
• UAE
• Rest of LAMEA